Pompe Disease: Opportunity Analysis and Forecasts to 2027

2018-11-27
Price :
Published : Nov-2018
No. of Pages : 86

Pompe Disease: Opportunity Analysis and Forecasts to 2027

Summary

Pompe disease (PD) is a rare genetic disorder resulting in the accumulation of glycogen with lysosomes in various tissues of the body. It is caused by a multitude of different phenotypical mutations to the GAA gene which is responsible for the transcription of ?-glucosidase. ?-glucosidase is responsible for glycogen degradation through enzymatic cleavage. PD is characterized by two types: infantile-onset Pomp disease (IOPD) and late-onset Pompe disease (LOPD). IOPD tends to be caused a severe deficiency or entire absence of GAA, resulting in symptoms being apparent from birth. Sufferers of IOPD tend to not reach their second birthday. LOPD has a large spectrum of severity, with symptoms manifesting typically in early adulthood. Sufferers have known to live a full life span if diagnosed early and given enzyme replacement therapy (ERT) to slow the progression of the disease.

GlobalData estimates the 2017 sales for the PD market at approximately $684 million across the 8MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), Brazil and Japan. By 2027 GlobalData expects the overall market to grow at a moderate compound annual growth rate (CAGR) of 2.8% to reach sales of $903 million over the 10-year period. The US market is anticipated to grow the fastest of the three regions, recording a CAGR of 4.9%, while the 5EU and Japan will each record CAGRs of 1.2% and 0.6%, respectively. At the end of 2027, the US will contribute around 51.9% of global sales, while the 5EU and Japan will account for 35.7% and 10.3% of global sales, respectively. The higher sales numbers for the US can be attributed to the higher price of pharmaceuticals and the greater diagnosed prevalence of PD.

Key Questions Answered

– ERT therapies are currently the cornerstone of PD treatment. Patients typically receive therapy from diagnosis to receive reduce glycogen accumulation. Nevertheless, ERT therapy cannot cross the blood brain barrier causing inevitable deterioration of the CNS resulting in death. Because of this, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the PD market with novel mechanisms of action?
– The current late-stage PD pipeline encompasses one additional ERT therapy being development by the current market drug owners Sanofi Genzyme. Will the late-stage drug make a significant impact on the PD market? Will this late-stage developmental drug capture a share of the PD market? and why?

Scope

– Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized PD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market.
– Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized PD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global PD therapeutics market from 2017-2027.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019" provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprie......
$2500

Encephalitis Global Clinical Trials Review, H1, 2019

Encephalitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Encephalitis Global Clinical Trials Review, H1, 2019" provides an overview of Encephalitis clinical trials scenario. This report provides top line data relating to the clinical trials on Encephalitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019

Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019" provides an overview of Dental Pain (Toothache/Tooth Pain) clinical trials scenario. This report provides top line data relating to the clinical trials on Dental Pain (Toothache/Tooth Pain). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Duodenal Cancer Global Clinical Trials Review, H1, 2019

Duodenal Cancer Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Duodenal Cancer Global Clinical Trials Review, H1, 2019" provides an overview of Duodenal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Duodenal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy